The Medicines Co. is aiming to file for US and EU approval of its novel PCSK9 inhibitor inclisiran in the second half of 2019, following an "aggressive and thoughtful" Phase III program emboldened by updated data from the Phase II ORION-1 study.
One-year results presented in a late-breaking clinical trials session at the European Society of Cardiology meeting in Barcelona on Aug....







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)